Immune Checkpoint Inhibitor-Induced Psoriasis

Immune checkpoint inhibitors (ICIs) are effective antitumor agents but are associated with immune-related adverse events. ICI-induced psoriasis commonly presents in patients with a history of psoriasis but may occur de novo, and it has a significant physical and psychosocial impact. ICI-induced and non-ICI-induced psoriasis are likely mediated by similar cytokines, and similar treatments are employed. Topical treatment often suffices, and when needed, several systemic treatments appear to be effective without impacting antitumor response. Development of psoriasis may indicate a superior response to ICIs. Thus, recognition and management of ICI-induced psoriasis is essential to avoid ICI interruption and maximize therapeutic potential.

Source: Dermatologic Clinics - March 15, 2024 Category: Dermatology Authors: Jolanta J. Pach, Nina Mbonu, Shaman Bhullar, Jeffrey M. Cohen, Jonathan S. Leventhal Source Type: research